General practitioner visit · children with asthma
Caseworker‐assigned discharge plans showed no clear difference in general practitioner visit compared with non‐caseworker‐assigned plans (low certainty).
1 finding from 1 review
Mortality (all‐cause) · patients with chronic obstructive pulmonary disease
It is very uncertain whether once‐daily ICS/LABA combined inhalers changes mortality (all‐cause) compared with once‐daily LAMA (very low certainty).
1 finding from 1 review
Any COPD exacerbation that requires short‐burst oral corticosteroids or antibiotics, or both · patients with chronic obstructive pulmonary disease
It is very uncertain whether once‐daily ICS/LABA combined inhalers changes any COPD exacerbation that requires short‐burst oral corticosteroids… compared with once‐daily LAMA (very low certainty).
1 finding from 1 review
Pneumonia · patients with chronic obstructive pulmonary disease
It is very uncertain whether once‐daily ICS/LABA combined inhalers changes pneumonia compared with once‐daily LAMA (very low certainty).
1 finding from 1 review
Quality of life · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Hospital admissions · patients with chronic obstructive pulmonary disease
It is very uncertain whether once‐daily ICS/LABA combined inhalers changes hospital admissions (all‐cause) compared with once‐daily LAMA (very low certainty).
1 finding from 1 review
Exacerbations leading to intubation · patients with chronic obstructive pulmonary disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Physical activity measure (e.g. 6MWT) · patients with chronic obstructive pulmonary disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Exacerbations · autumn asthma exacerbations in children
Omalizumab probably leads to lower exacerbations compared with usual care (moderate certainty).
3 findings from 1 review
OR 0.48 [0.25, 0.92]
1 study · 348 participants
Moderate
OR 0.37 [0.17, 0.81]
1 study · 184 participants
Moderate
OR 0.63 [0.22, 1.79]
1 study · 164 participants
Moderate
Exacerbations · autumn asthma exacerbations in children
The review found no eligible studies for this question.
2 findings from 1 review
Adverse events · autumn asthma exacerbations in children
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · autumn asthma exacerbations in children
Omalizumab showed no clear difference in adverse events compared with usual care (moderate certainty).
1 finding from 1 review
Exacerbations · autumn asthma exacerbations in children
A boost of inhaled corticosteroids showed no clear difference in exacerbations compared with usual care (moderate certainty).
1 finding from 1 review
Adverse events · autumn asthma exacerbations in children
A boost of inhaled corticosteroids showed no clear difference in adverse events compared with usual care (moderate certainty).
1 finding from 1 review
Exacerbations · autumn asthma exacerbations in children
The review found no eligible studies for this question.
2 findings from 1 review
Adverse events · autumn asthma exacerbations in children
Leukotriene receptor antagonist showed no clear difference in adverse events compared with usual care (high certainty).
1 finding from 1 review
Exacerbations (number of people experiencing ≥ 1 exacerbations) · adults with bronchiectasis
Macrolides probably leads to lower ≥ 1 exacerbation compared with placebo (moderate certainty).
1 finding from 1 review
All‐cause mortality · adults with bronchiectasis
1 finding from 1 review
SGRQ Total SGRQ (Total) Score. Scale from: 0 to 100. Lower score indicates better quality of life. · adults with bronchiectasis
1 finding from 1 review
Change in SGRQ total score · adults with bronchiectasis
1 finding from 1 review